ProCE Banner Activity

Expert Answers to Frequently Asked Questions About Selective RET Inhibition in RET-Driven Cancers

Clinical Thought

Read expert answers to key questions asked by healthcare professionals during a series of live webinars focused on the optimal use of selective RET inhibitors in the treatment of advanced cancers with RET alterations, including how to differentiate between these agents and what to do after progression on them.

Released: May 11, 2021

Expiration: May 10, 2022

Share

Faculty

Joshua Bauml

Joshua Bauml, MD

Instructor, Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania
Staff Physician
Philadelphia VA Medical Center
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Joshua Bauml, MD

Instructor, Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania
Staff Physician
Philadelphia VA Medical Center
Philadelphia, Pennsylvania

Joshua Bauml, MD, has disclosed that he has received consulting fees from AstraZeneca, Ayala, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Clovis, Genentech, Guardant Health, Inivata, Janssen, Merck, Novartis, Regeneron, and Takeda and funds for research support from AstraZeneca, Bayer, Carevive Systems, Carisma Therapeutics, Clovis, Janssen, Merck, Novartis, and Takeda.